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Abstract
Polycystic liver disease (PLD) is characterized by the 
presence of multiple bile duct-derived epithelial cysts 
scattered in the liver parenchyma. PLD can manifest itself 
in patients with severe autosomal dominant polycystic 
kidney disease (ADPKD). Isolated autosomal dominant 
polycystic liver disease (ADPLD) is genetically distinct 
from PLD associated with ADPKD, although it may 
have similar pathogenesis and clinical manifestations. 
Recently, mutations in two causative genes for ADPLD, 
independently from ADPKD, have been identified. We 
report here a family (a mother and her daughter) with 
a severe form of ADPLD not associated with ADPKD 
produced by a novel missense protein kinase C substrate 
80K-H (PRKCSH) mutation (R281W). This mutation 
causes a severe phenotype, since the two affected 
subjects manifested signs of portal hypertension. Doppler 
sonography, computed tomography (CT) and magnetic 
resonance (MR) imaging are effective in documenting 
the underlying lesions in a non-invasive way.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Proof  of  existence of  autosomal dominant polycystic 
liver disease (ADPLD) as a distinct genetic entity, 
independently from autosomal dominant polycystic 
kidney disease (ADPKD), stems from three studies in 
which isolated familial polycystic liver disease (PLD) was 
shown to be unlinked to the PKD1 or PKD2 loci[1-3]. 
In 2000, Reynolds et al.[4] identified a locus for ADPLD 
on chromosome 19p13.2-13.1. In 2003, two independent 
groups demonstrated that mutations in PRKCSH, encoding 
the β-subunit of  glucosidase II, a N-linked glycan-
processing enzyme in the endoplasmic reticulum, cause 
isolated ADPLD[5,6]. Given its role in the pathogenesis of  
ADPLD, this protein has been renamed as hepatocystin[5]. 
Very recently, Davila et al.[7] found that mutations in SEC63 
(chromosome 6q21), encoding a component of  the protein 
translocation machinery in the endoplasmic reticulum, also 
cause ADPLD. Mutations in PRKCSH and SEC63 probably 
account for less than one-third of  ADPLD cases, indicating 
that there is at least one more locus associated with this 
disease[7,8].
We have reported here the fi rst Spanish family with a 
severe form of  ADPLD not associated with ADPKD. The 
proband manifested displacement of  abdominal structures 
by a massively enlarged liver causing portal hypertension 
and inferior vena cava compression.
CASE REPORT
A 36-year-old woman presented with a long history 
of  abdominal enlargement. She had two pregnancies 
and live births at 29 and 34 years of  age, respectively. 
Physical examination showed a bulging abdomen with a 
palpable mass extending from the right hemiabdomen 
to the left quadrant reaching 10 cm below the umbilicus. 
Laboratory data showed 0.9 mg/dL creatinine (normal 
range 0.6-1.2 mg/dL), 7.2 g/dL total proteins (normal 
range 6-8 g/dL), 137 mg/dL total cholesterol (normal 
range 140-220 mg/dL) , 30 mg/dL t r ig l ycer ides 
(normal range 50-128 mg/dL), 29 IU/L aspartate 
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12-16 g/dL), 66.6 fL MCV (80-100 fL), 21.8 pg MCH 
(normal range 26-34 pg), 5.9% hemoglobin A2 (normal 
range 2-3.5%), 3 500/μL white blood cell with normal 
differentiation, 105 000/mm3 platelet count, 0.6 mg/dL 
creatinine, 6.9 g/dL total proteins, 177 mg/dL total 
cholesterol, 101 mg/dL triglycerides, 31 IU/L aspartate 
aminotransferase, 19 IU/L alanine aminotransferase, 
14 IU/L gamma glutamyl transpeptidase, 109 IU/L alkaline 
phosphatase, 2.1 mg/dL total bilirubin, 79% prothrombin 
time and 362 mg/dL fibrinogen. Ultrasonography and 
CT of  the abdomen demonstrated PLD. There were signs 
of  portal hypertension with varices in the hepatic hilum, 
gastrohepatic ligament, and lower esophagus. The spleen 
was enlarged, measuring 17.6 cm in length. The kidneys 
were normal. The patient was healthy and had no variceal 
bleeding. She refused any invasive procedure. 
DNA sequencing and mutation detection
DNA was isolated from peripheral blood leukocytes by 
standard procedures. We performed polymerase chain 
reaction amplification using specific primer sets for all 
the 18 exons that constitute the open reading frame of  
PRKCSH. We determined the nucleotide sequences of  the 
amplifi ed fragments by fl uorescence sequencing with dye-
terminator chemistry on an ABI3700 capillary sequencer 
(Perkin-Elmer Applied Biosystems).
RESULTS
Sequence analysis of  PRKCSH gene from DNA isolated 
from the proband demonstrated a base pair change (C>T) 
on one allele at position 841 (Figure 3). This mutation 
located in exon 10 resulted in a change of  the amino acid 
composition of  hepatocystin with the replacement of  
arginine to tryptophan at codon (R281W). The missense 
mutation was also present in the affected mother of  the 
proband but not in her two children. Within hepatocystin, 
the mutation was located between the EF-hand calcium-
binding domain, ending at codon 234 and the glutamic 
acid-rich region which starts at codon 299 (Figure 4). 
Hepatocystin, the protein product of  PRKCSH, comprises 
528 amino acid residues and has a predicted molecular 
mass of  approximately 59 ku. This protein contains a 
signal peptide for translocation across the endoplasmic 
aminotransferase (normal range 10-40 IU/L), 22 IU/L 
alanine aminotransferase (normal range 10-40 IU/L), 
135 IU/L gamma glutamyl transpeptidase (normal 
range 10-40 IU/L), 117 IU/L alkaline phosphatase 
(normal range 40-105 IU/L), 1.1 mg/dL total bilirubin 
(normal range 0.1-1.0 mg/dL), 82% prothrombin time 
and 394 mg/dL fibrinogen (normal range 200-400 
mg/dL). Sonography and computed tomography (CT) 
of  the abdomen were compatible with an increased liver 
volume caused by numerous hepatic cysts of  various 
sizes. Magnetic resonance (MR) imaging of  the abdomen 
revealed a massive polycystic liver with caudal and posterior 
displacement of  the abdominal organs (Figures 1A and B). 
Doppler sonography and MR angiography demonstrated 
displacement of  the kidneys and their vascular structures 
by the massively enlarged polycystic liver. The celiac axis 
was also displaced and the portal vein and a segment of  the 
inferior vena cava below the hepatic veins were compressed 
by the hepatic cysts (Figure 1C). The kidneys were normal 
except for two small cortical cysts on the left kidney. There 
were signs of  moderate portal hypertension with varices 
in the hepatic hilum. Seven years after the diagnosis, the 
patient was healthy and free of  complications. Currently 
she is awaiting a liver transplantation. 
Family history revealed that the patient’s mother 
also had PLD without kidney disease. The father was 
not known to suffer from liver or kidney disease. The 
proband’s daughters had no renal or hepatic cysts. The 
family pedigree is represented in Figure 2. The proband’s 
mother (age 72 years) had a history of  cholecystectomy in 
1983 (performed in another hospital) and a diagnosis of  
heterozygous beta thalassemia minor in 1990. She had one 
daughter. Laboratory data showed 37% hematocrit (normal 
range 36-46%), 12.2 g/dL hemoglobin (normal range 
Figure 1 Massive polycystic liver disease on coronal MR imaging (A), caudal 
and posterior displacement of abdominal organs by the massively enlarged liver 
on sagittal MR imaging (B), and compression of the inferior vena cava (arrow) 
produced by the massively enlarged liver (C) on MR angiograph.
Figure 2 Family pedigree of the patient.
G AT G GACCGC G GA C TAA C
↓
Asp Lys Tyr Trp Ser Glu
Arg
↓
T
Figure 3 Sequence identifi cation of the C>T changes in exon 10. This mutation, 
C841T which is predicted to change the amino acid composition of hepatocystin, 
changes arginine to tryptophan at codon 281 (R281W).
↑Proband
A
C
B
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bile duct cells that have undergone somatic second hits[7,13,14]. 
However, the two-hit model has not been investigated in 
isolated PLD. 
The clinical profile of  PLD has been defined by 
Qian et al.[16] who on the basis of  a small series concluded 
that extra hepatic manifestations are infrequent but may 
include simple renal cysts, intracranial aneurysms, and 
mitral valve abnormalities. Genotype-phenotype relations 
remain speculative at this point. Liver cysts are usually 
asymptomatic, and as a consequence, the disease may 
go undetected and is likely to be underdiagnosed in the 
general population[17]. Symptoms occurred are caused 
by the mass effect of  the cysts, or the development of  
complications such as hemorrhage, infection, or rupture 
of  cysts. Symptoms caused by the mass effect of  the cysts 
include vague abdominal distension, early satiety, dyspnea, 
and back pain. Rarely, ascites can form because of  hepatic 
venous outflow obstruction by cysts. Lower extremity 
edema is secondary to extrinsic compression of  the 
inferior vena cava, hepatic veins, or portal vein by large or 
by many small or medium size hepatic cysts. Compression 
of  the bile ducts can cause jaundice. The symptoms of  
compression or thrombosis of  the inferior vena cava may 
be obscure and a high index of  suspicion is required for 
the diagnosis[18]. Liver metabolic and synthetic functions 
remain normal, although an increase in serum levels of  
alkaline phosphatase, bilirubin and gamma glutamyl 
transpeptidase, and a decrease in serum levels of  total 
cholesterol and triglycerides have been described in some 
cases[16]. The factors that affect disease progression are 
unclear. However, some risk factors for the progression of  
the disease are age, sex, number of  pregnancies, and use 
of  estrogen[14,16]. 
The proband manifested a massively enlarged liver, 
which caused abdominal heaviness and progressive 
hemodynamic changes. She presented displacement of  
abdominal structures by the massively enlarged liver 
and hepatic cysts not only caused extrinsic compression 
of  the inferior vena cava, but also were responsible for 
portal hypertension. Whereas laboratory studies in the 
proband disclosed a slight increase in the serum levels of  
alkaline phosphatase and gamma glutamyl transpeptidase, 
and a decrease in serum levels of  total cholesterol 
and triglycerides, the proband’s mother presented 
thrombocytopenia and a slight increase in total bilirubin. 
reticulum membrane, a low-density lipoprotein receptor 
domain class A (LDLa) domain, two EF-hand domains, 
a glutamic-acid-rich region, a mannose-6-phosphate 
receptor domain and a conserved C-terminal HDEL 
amino acid sequence for endoplasmic reticulum retention. 
Hepatocystin is an endoplasmic reticulum-resident enzyme 
that is involved in carbohydrate processing and quality 
control of  newly synthesized glycoproteins.
DISCUSSION
ADPLD is a rare autosomal dominant disorder that has 
been described in fewer than 50 families from Finnish[8], 
Dutch[5], American[4], Belgian[2], and Spanish-Belgian[3] 
ancestry. The pathology of  ADPLD consists of  numerous 
cysts of  biliary epithelial origin spread throughout the liver 
parenchyma. This disease is distinct from ADPKD1 and 
ADPKD2, in which affected individuals develop bilateral 
renal cysts and liver and pancreatic cysts in advanced 
cases[9-11]. Cystic liver disease occurs in a substantial portion 
of  patients with ADPKD and end-stage renal disease. 
Factors influencing the prevalence of  PLD in ADPKD 
include female sex, age (prevalence of  PLD is 10% in the 
third decade, but 60% in patients older than 60 years), and 
pregnancy (multiparity is associated with increased size and 
number of  cysts in ADPKD)[12]. 
The recent cloning of  the gene involved in ADPLD 
has greatly facilitated the possibility of  a fi rm molecular 
diagnosis in our family. Up to now, a total of  nine different 
PRKCSH mutations have been described[13,14]. We detected 
a novel missense PRKCSH mutation (R281W) in our 
family. Several lines of  evidence suggest that the R281W 
represents a bona fide disease causing mutation. First, 
there is segregation of  the mutation with the disease in our 
family. Second, arginine, a positively charged amino acid 
is replaced by tryptophan which is neutral. Lastly, the C 
at position 841 is highly conserved among the species 
(Table 1). 
As is the case for ADPKD, ADPLD is clinically and 
genetically heterogeneous[8-14]. Although isolated PLD is 
genetically distinct from PLD associated with ADPKD, 
both diseases may have similar pathogenesis and clinical 
manifestations. If  ADPLD, like ADPKD[15], occurs by 
a cellular recessive, two-hit mechanism, then mutations 
in either PRKCSH or SEC63 will result in loss of  proper 
folding of  integral membrane or secreted glycoproteins in 
↓
↓
↓
↓
↓↓
↓
C841T
0 100 200 300 400 500 600 700
LDLa EF Glutamicrich M6P
216insA 374-375delAG 898+2 T>C 1168insC 1338-2 A>G
C1237T
1437+2delTG
C1266G
292+1 G>C
↓
↓
Figure 4 Schematic representation of hepatocystin. The position of PRKCSH 
mutations that have been associated with PCLD are superimposed on the 
structure of hepatocystin. The new mutation detected in our family is indicated on 
top. The numbers refl ect the amino acid numbering of hepatocystin. LDLa: low-
density lipoprotein receptor domain A; EF: EF-hand calcium-binding domains; 
MPR: mannose 6-phosphate receptor domain.
Table 1 Missense PRKCSH mutation detected in our family
                                    278    279            280                   281
Species               Asp    Lys            Tyr                  Arg
HS                     G      A       C       A       A       G     T      A       C      C      G       G
BT                     G      A        C       A       A      G     T      A       C      C      G       G
MM                  G      A        C       A       A      G     T      A       C      C      G       C
RN                    G      A        C      A        A      G     T      A       C      C      G       C
Patients            G      A      C      A        A      G     T      A       C      T       G      G
HS: Homo sapiens; BT: Bos Taurus; MM: Mus musculus, RN: Rattus norvegicus. 
The C841T PRKCSH mutation detected in this study is indicated in bold, 
and for comparison the corresponding nucleotides from various species are 
included. The numbers on top correspond with the codon numbering of 
hepatocystin, while Asp is aspartic acid; Lys is lysine; Tyr is tyrosine; Arg 
is arginine. Note that the C at position 841 is highly conserved among the 
species.
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As the proband’s history shows, the disease may become 
highly symptomatic in young women. The more severe 
extensive development of  the condition in the proband 
than in her affected mother contrasts with the reported 
greater severity of  the liver involvement with age. The 
increased severity of  the disease in the proband could 
be in relation, at least in part, with repeated pregnancies 
in this patient. However, other possible factors for the 
progression of  the disease remain unknown. Screening 
of  the at-risk members of  the families of  other affected 
patients could help to answer this question.
The presence of  (few) renal cysts, as demonstrated in 
our proband who had 2 renal cysts does not preclude the 
diagnosis ADPLD. This is in accord with the data from 
another study that demonstrated PRKCSH mutations in 
four patients with polycystic livers who possessed at least 
one renal cyst[14].
Most patients with PLD require no treatment. In 
highly symptomatic patients, percutaneous cyst aspiration, 
sclerosis and cyst fenestration may be indicated[16]. In 
patients with diffuse cystic liver, hepatic resection[19] is 
often the only possibility but entails a high mortality 
rate. Stent placement in the inferior vena cava has been 
successfully applied in a few well-selected patients 
with only inferior vena cava compression. In patients 
with severe phenotype, liver transplantation should be 
considered[20]. In our patients, due to the size of  their liver, 
resection of  the lobes of  their livers for decompression 
was deemed to be problematic and liver transplantation 
was considered as the better option in the proband.
In summary, we have described here a family with a 
severe form of  ADPLD not associated with ADPKD, and 
a novel PRKCSH mutation that was vertically transmitted. 
The two affected subjects manifested signs of  portal 
hypertension. This family underlines the need for a careful 
investigation of  patients with otherwise unexplained liver 
cystic disease, focusing on whether other organ systems are 
involved. It also stresses the importance of  accurate family 
investigation whenever possible. Doppler sonography, 
CT, and MR are effective in documenting the underlying 
lesions non-invasively.
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